Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019

Respirology Case Reports

卷:9

Masako Kadowaki¹  Hiroaki Ogata²  Atsushi Moriwaki²  Akiko Ishimatsu²  Makoto Yoshida²  Taisuke Nakagawa²  Kazuhito Taguchi²  Soichiro Sakoda² 

[1] Department of Infectious Diseases National Hospital Organization Fukuoka National Hospital Fukuoka Japan;

[2] Department of Respiratory Medicine National Hospital Organization Fukuoka National Hospital Fukuoka Japan;

关键词: Acute respiratory distress syndrome;    coronavirus disease 2019;    nintedanib;    pulmonary fibrosis;    severe acute respiratory syndrome coronavirus 2;   

DOI  :  10.1002/rcr2.744

来源: DOAJ

【 摘 要 】

Abstract A 78‐year‐old Japanese woman with no smoking history suffered from near‐fatal coronavirus disease 2019 (COVID‐19) requiring four‐week invasive mechanical ventilation, with subsequent radiological features of pulmonary fibrosis. Although methylprednisolone gradually improved her respiratory condition, her oxygenation and exercise tolerance had drastically deteriorated, necessitating high‐flow nasal cannula oxygen therapy. In parallel with tapering systemic steroid, the patient was treated with nintedanib. Three months later, the patient was able to walk with a walking aid using oxygen at 4 L/min. The present case is an indication that nintedanib might provide a novel therapeutic approach for managing post‐COVID‐19 fibrosis, although further studies are warranted.

【 授权许可】

Unknown